Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
์ข
๋ชฉ ์ฝ๋ MYNZ
ํ์ฌ ์ด๋ฆMainz Biomed NV
์์ฅ์ผNov 04, 2021
CEOBaechler (Guido)
์ง์ ์19
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃNov 04
์ฃผ์Sirius Gutenberg Park
๋์MAINZ
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐGermany
์ฐํธ ๋ฒํธ55129
์ ํ496131265140
์น์ฌ์ดํธhttps://www.mainzbiomed.com/
์ข
๋ชฉ ์ฝ๋ MYNZ
์์ฅ์ผNov 04, 2021
CEOBaechler (Guido)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์